Categories

Biopower Market – Global Market Size, Average Price, Major Feedstock, Regulations, and Key Country Analysis to 2025

US$ 3995

Biopower Market – Global Market Size, Average Price, Major Feedstock, Regulations, and Key Country Analysis to 2025″”, the latest report from industry analysis specialist GlobalData, offers comprehensive information and analysis of the global biopower market.

10-17 2016   Pages: 288

Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB)

US$ 3500

Global Markets Direct’s, ‘Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) – Pipeline Review, H1 2016’, provides in depth analysis on Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) targeted pipeline therapeutics.

08-29 2016   Pages: 37

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

US$ 2500

Global Markets Direct’s, ‘Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline Review, H1 2016’, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline landscape.

08-29 2016   Pages: 1371

Colorectal Cancer

US$ 2500

Global Markets Direct’s, ‘Colorectal Cancer – Pipeline Review, H1 2016’, provides an overview of the Colorectal Cancer pipeline landscape.

08-29 2016   Pages: 1564

HIV / AIDS

US$ 2500

Global Markets Direct’s, ‘HIV / AIDS – Pipeline Review, H1 2016’, provides an overview of the HIV / AIDS pipeline landscape.

The report provides comprehensive information on the therapeutics under development for HIV / AIDS, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for HIV / AIDS and features dormant and discontinued projects.

08-29 2016   Pages: 886

Melanoma

US$ 2500

Global Markets Direct’s, ‘Melanoma – Pipeline Review, H1 2016’, provides an overview of the Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects.

08-29 2016   Pages: 1479

Breast Cancer

US$ 2500

Global Markets Direct’s, ‘Breast Cancer – Pipeline Review, H1 2016’, provides an overview of the Breast Cancer pipeline landscape.

08-29 2016   Pages: 3011

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12)

US$ 3500

Global Markets Direct’s, ‘Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) – Pipeline Review, H1 2016’, provides in depth analysis on Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) targeted pipeline therapeutics.

08-29 2016   Pages: 62

HIV-1 Integrase (EC 2.7.7.)

US$ 3500

Global Markets Direct’s, ‘HIV-1 Integrase (EC 2.7.7.) – Pipeline Review, H1 2016’, provides in depth analysis on HIV-1 Integrase (EC 2.7.7.) targeted pipeline therapeutics.

08-29 2016   Pages: 70

Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Beta (I-Kappa B Kinase Beta or Nuclear Factor NF-Kappa-B Inhibitor Kinase Beta or IKBKB or I-Kappa-B Kinase 2 or IKK2 or NFKBIKB or EC 2.7.11.10)

US$ 3500

Global Markets Direct’s, ‘Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Beta (I-Kappa B Kinase Beta or Nuclear Factor NF-Kappa-B Inhibitor Kinase Beta or IKBKB or I-Kappa-B Kinase 2 or IKK2 or NFKBIKB or EC 2.7.11.10) – Pipeline Review, H1 2016’, provides in depth analysis on Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Beta (I-Kappa B Kinase Beta or Nuclear Factor NF-Kappa-B Inhibitor Kinase Beta or IKBKB or I-Kappa-B Kinase 2 or IKK2 or NFKBIKB or EC 2.7.11.10) targeted pipeline

08-29 2016   Pages: 39
Contact With Us
Join templatemonster at google+
Customized Research
Request Sample